A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
NCT07473726
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced/Metastatic Solid Tumors
Interventions
DRUG:
HLX48
Sponsor
Shanghai Henlius Biotech